Research Topics
| Cynthia A BossieSummaryAffiliation: Johnson and Johnson Pharmaceutical Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialCynthia A Bossie
Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA
BMC Psychiatry 11:79. 2011..These post-hoc analyses addressed two commonly encountered clinical issues regarding the initiation dosing: the time to onset of efficacy and the associated tolerability...
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophreniaCarla M Canuso
Ortho McNeil Janssen Scientific Affairs, Titusville, NJ, USA
Am J Psychiatry 166:691-701. 2009..The authors compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizophrenia requiring hospitalization...- Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysisIbrahim Turkoz
Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA
BMC Psychiatry 11:21. 2011..To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology... - A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorderCarla M Canuso
Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Rd E12604, Titusville, NJ 08560, USA
J Clin Psychiatry 71:587-98. 2010..This study was designed to assess efficacy and safety of paliperidone extended-release (ER) in patients with schizoaffective disorder... - Paliperidone extended-release tablets in patients with recently diagnosed schizophreniaCarla M Canuso
Ortho McNeil Janssen Scientific Affairs, LLC, Titusville New Jersey, USA
Early Interv Psychiatry 4:64-78. 2010..Effective early and persistent antipsychotic treatment in recently diagnosed schizophrenia may positively impact long-term outcomes. Paliperidone extended-release (ER) was assessed in this population... - Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptomsCarla M Canuso
Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560 0200, USA
J Affect Disord 120:193-9. 2010..This post-hoc analysis evaluated the effects of paliperidone extended-release (ER) in patients with schizophrenia and prominent affective symptoms... - Psychotic symptoms in patients with bipolar maniaCarla M Canuso
Ortho McNeil Janssen Scientific Affairs, L L C, Titusville, New Jersey 08560, United States
J Affect Disord 111:164-9. 2008..Psychosis has been identified in as many as 68% of patients with bipolar mania. This analysis identified psychotic symptoms in these patients... 
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term studyGeorges M Gharabawi
Medical Affairs Division, Janssen Pharmaceutica Products, L P, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
Schizophr Res 77:129-39. 2005..This analysis assessed TD by defined research criteria in patients receiving long-acting, injectable risperidone...- Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injectionRobert A Lasser
Global Medical Strategy, Johnson and Johnson Pharmaceutical Services, LLC, Raritan, NJ 08869, USA
Schizophr Res 77:215-27. 2005..Recently proposed criteria for remission (mild or less on multiple core-symptom ratings for at least 6 months) have been applied to a 1-year study of long-acting risperidone injection... - Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizersCarla M Canuso
Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA
J Clin Psychopharmacol 30:487-95. 2010..Paliperidone ER improved psychotic and affective symptoms both as monotherapy and as an adjunct to MS/AD. No new safety findings were observed in this population... - Risperidone long-acting therapy in stable patients with recently diagnosed schizophreniaWayne Macfadden
Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA
Int Clin Psychopharmacol 25:75-82. 2010..2%), anxiety (12.3 vs. 17.3%), and influenza (10.5 vs. 5.3%). These findings confirm the benefit of RLAT in patients with schizophrenia and suggest that earlier treatment with long-acting preparations is associated with better outcomes... - Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidoneGeorges M Gharabawi
Medical Affairs, Janssen Pharmaceutica Inc, Titusville, New Jersey 08560, USA
Int Clin Psychopharmacol 21:233-40. 2006..Associations were noted between patient-rated quality of life and specific symptom domains, but not insight... - Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trialGeorges M Gharabawi
Medical Affairs, Janssen Pharmaceutica Inc, Titusville, NJ, USA
BMC Psychiatry 6:45. 2006..Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent exacerbation of schizophrenia... - Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trialRobert A Lasser
Janssen Psychiatry, LLC, Titusville, NJ 08560, USA
Int J Neuropsychopharmacol 8:427-38. 2005..Psychotic patients considered stable but symptomatic with oral risperidone treatment showed further improvements in symptom ratings and extrapyramidal dysfunction during a year of bi-weekly injections of long-acting risperidone... - Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidoneJennifer Kern Sliwa
Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, USA
Schizophr Res 132:28-34. 2011..To examine efficacy and safety of acute treatment with paliperidone palmitate in subjects with schizophrenia whose disease remained symptomatic despite recent treatment with oral risperidone... - Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorderRobert Lasser
Janssen Pharmaceutical Products, LP, Titusville, NJ, USA
J Affect Disord 83:263-75. 2004.... - Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorderNatalie Ciliberto
Medical Services CNS, Medical Affairs Division, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
Int Clin Psychopharmacol 20:207-12. 2005..ESRS scores were low throughout the study, and no significant impact of race was observed. Overall rates of AEs were similar among the racial groups. Race did not appear to impact the efficacy and tolerability of long-acting risperidone... - Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidoneCarla M Canuso
Ortho McNeil Janssen Scientific Affairs LLC, Titusville, NJ, USA
Int Clin Psychopharmacol 23:209-15. 2008..4% with placebo. In patients who had received risperidone previously but remained sufficiently symptomatic for enrollment, paliperidone ER was significantly more effective than placebo in reducing symptoms and producing functional gains... - Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesiaGeorges M Gharabawi
Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, NJ 08560, USA
Schizophr Res 77:119-28. 2005.... - Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa
Janssen Scientific Affairs LLC, Titusville, NJ, USA
Neuropsychiatr Dis Treat 8:375-85. 2012.... - Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorderRobert A Lasser
Janssen Medical Affairs, LLC, Titusville, New Jersey 08560, USA
Int J Geriatr Psychiatry 19:898-905. 2004..Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long-acting risperidone, the first long-acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery... - Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trialGahan J Pandina
Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, NJ 08560, USA
J Autism Dev Disord 37:367-73. 2007..7.2 (1.4), P<0.05; ES=-0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism... - Role of paliperidone extended-release in treatment of schizoaffective disorderCarla M Canuso
External Innovation Neuroscience Therapeutic Area, Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ, USA
Neuropsychiatr Dis Treat 6:667-79. 2010..To the best of our awareness, these pooled data provide the largest data set of patients with schizoaffective disorder, and extend our knowledge of disease characteristics and treatment response... - A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaWayne Macfadden
Dr Macfadden was with Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, at the time of this analysis Dr Macfadden currently is Medical Director at Princeton Medical Institute, Princeton, New Jersey Drs Ma and Haskins are with Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey and Drs Bossie and Alphs are with Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey
Psychiatry (Edgmont) 7:23-31. 2010.... - Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophreniaIbrahim Turkoz
Ortho McNeil Janssen Scientific, Affairs, LLC, Titusville, NJ, USA
Neuropsychiatr Dis Treat 4:949-58. 2008..1% inverse effect. Path analysis indicated that paliperidone ER has a direct effect on negative symptoms. Negative symptom improvement also was indirectly mediated via changes in positive and depressive symptoms... - Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialLarry Alphs
Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
Ann Gen Psychiatry 10:12. 2011..abstract:.. - Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneRobert A Lasser
Janssen Medical Affairs, LLC 1125 Trenton Harbourton Road, Office A20904, Titusville, NJ 08560 0200, USA
Eur Psychiatry 19:219-25. 2004..This report examines 50-weeks of long-acting risperidone therapy in patients previously stabilized with conventional depot antipsychotics...